-

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST.

A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781. A replay will be available for 90 days after the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contacts

Jessica Hanover – Vice President, Corporate Affairs
Cerus Corporation
925-288-6137

Industry:

Cerus Corporation

NASDAQ:CERS
Release Versions
English

Contacts

Jessica Hanover – Vice President, Corporate Affairs
Cerus Corporation
925-288-6137

More News From Cerus Corporation

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the...

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus’ chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex...

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world’s blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru...
Back to Newsroom